Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis

Abstract Reduced amplitude of mismatch negativity (MMN) is one of the more promising biological markers of schizophrenia. This finding holds true in both early and chronic phases of the disorder, and is compatible with the glutamatergic dysfunction hypothesis. To further establish MMN as a biomarker...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tatsuya Nagai, Kenji Kirihara, Mariko Tada, Daisuke Koshiyama, Shinsuke Koike, Motomu Suga, Tsuyoshi Araki, Kenji Hashimoto, Kiyoto Kasai
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f0801c5b20404839914dd999509abbd8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f0801c5b20404839914dd999509abbd8
record_format	dspace
spelling	oai:doaj.org-article:f0801c5b20404839914dd999509abbd82021-12-02T15:05:44ZReduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis10.1038/s41598-017-02267-12045-2322https://doaj.org/article/f0801c5b20404839914dd999509abbd82017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02267-1https://doaj.org/toc/2045-2322Abstract Reduced amplitude of mismatch negativity (MMN) is one of the more promising biological markers of schizophrenia. This finding holds true in both early and chronic phases of the disorder, and is compatible with the glutamatergic dysfunction hypothesis. To further establish MMN as a biomarker of aberrant glutamatergic neurotransmission, an exploration for an association with blood levels of glutamatergic amino acids is an important next step. Despite a large body of work investigating MMN in schizophrenia, no previous studies have undertaken this endeavor. Nineteen patients with first-episode psychosis (FEP), 21 ultra-high risk individuals (UHR), and 16 healthy controls (HC) participated in the study. The MMNs in response to duration change (dMMN) and frequency change (fMMN) were measured. The fasting plasma levels of glutamate, glutamine, glycine, D-serine, and L-serine were measured. dMMN amplitudes were significantly reduced in FEP and UHR, compared to HC. The plasma levels of glutamate of FEP were significantly higher than those of HC. Higher plasma levels of glutamate were associated with smaller dMMN amplitudes in the FEP and HC groups. These findings are compatible with the hypothesis that MMN is a useful biological marker of aberrant glutamatergic neurotransmission in the early stages of schizophrenia.Tatsuya NagaiKenji KiriharaMariko TadaDaisuke KoshiyamaShinsuke KoikeMotomu SugaTsuyoshi ArakiKenji HashimotoKiyoto KasaiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Tatsuya Nagai Kenji Kirihara Mariko Tada Daisuke Koshiyama Shinsuke Koike Motomu Suga Tsuyoshi Araki Kenji Hashimoto Kiyoto Kasai Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis
description	Abstract Reduced amplitude of mismatch negativity (MMN) is one of the more promising biological markers of schizophrenia. This finding holds true in both early and chronic phases of the disorder, and is compatible with the glutamatergic dysfunction hypothesis. To further establish MMN as a biomarker of aberrant glutamatergic neurotransmission, an exploration for an association with blood levels of glutamatergic amino acids is an important next step. Despite a large body of work investigating MMN in schizophrenia, no previous studies have undertaken this endeavor. Nineteen patients with first-episode psychosis (FEP), 21 ultra-high risk individuals (UHR), and 16 healthy controls (HC) participated in the study. The MMNs in response to duration change (dMMN) and frequency change (fMMN) were measured. The fasting plasma levels of glutamate, glutamine, glycine, D-serine, and L-serine were measured. dMMN amplitudes were significantly reduced in FEP and UHR, compared to HC. The plasma levels of glutamate of FEP were significantly higher than those of HC. Higher plasma levels of glutamate were associated with smaller dMMN amplitudes in the FEP and HC groups. These findings are compatible with the hypothesis that MMN is a useful biological marker of aberrant glutamatergic neurotransmission in the early stages of schizophrenia.
format	article
author	Tatsuya Nagai Kenji Kirihara Mariko Tada Daisuke Koshiyama Shinsuke Koike Motomu Suga Tsuyoshi Araki Kenji Hashimoto Kiyoto Kasai
author_facet	Tatsuya Nagai Kenji Kirihara Mariko Tada Daisuke Koshiyama Shinsuke Koike Motomu Suga Tsuyoshi Araki Kenji Hashimoto Kiyoto Kasai
author_sort	Tatsuya Nagai
title	Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis
title_short	Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis
title_full	Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis
title_fullStr	Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis
title_full_unstemmed	Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis
title_sort	reduced mismatch negativity is associated with increased plasma level of glutamate in first-episode psychosis
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/f0801c5b20404839914dd999509abbd8
work_keys_str_mv	AT tatsuyanagai reducedmismatchnegativityisassociatedwithincreasedplasmalevelofglutamateinfirstepisodepsychosis AT kenjikirihara reducedmismatchnegativityisassociatedwithincreasedplasmalevelofglutamateinfirstepisodepsychosis AT marikotada reducedmismatchnegativityisassociatedwithincreasedplasmalevelofglutamateinfirstepisodepsychosis AT daisukekoshiyama reducedmismatchnegativityisassociatedwithincreasedplasmalevelofglutamateinfirstepisodepsychosis AT shinsukekoike reducedmismatchnegativityisassociatedwithincreasedplasmalevelofglutamateinfirstepisodepsychosis AT motomusuga reducedmismatchnegativityisassociatedwithincreasedplasmalevelofglutamateinfirstepisodepsychosis AT tsuyoshiaraki reducedmismatchnegativityisassociatedwithincreasedplasmalevelofglutamateinfirstepisodepsychosis AT kenjihashimoto reducedmismatchnegativityisassociatedwithincreasedplasmalevelofglutamateinfirstepisodepsychosis AT kiyotokasai reducedmismatchnegativityisassociatedwithincreasedplasmalevelofglutamateinfirstepisodepsychosis
_version_	1718388742770655232

Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis

Ejemplares similares